Stanford University Joins Cofactor Genomics’ Clinical Trial Evaluating Immunotherapy Predictive Diagnostic Assay Across 11 Cancers

SAN FRANCISCO–(BUSINESS WIRE)–Stanford University and Cofactor Genomics, the company bridging the precision medicine gap, announced today that Stanford will join Cofactor’s PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) clinical trial evaluating use of the company’s OncoPrism™ predictive diagnostic assay across 11 cancers. Cofactor’s patented approach to building…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks